文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

miR-126-5p对脓毒症诱导急性肾损伤的诊断价值及其通过CASP3的分子机制

Diagnostic Value of miR-126-5p in Sepsis-Induced Acute Kidney Injury and its Molecular Mechanism via CASP3.
PubMed 文献 · Shock · 2026-07-03
一句话结论SAKI患者血清miR-126-5p下调,与肾损伤标志物负相关,体外通过靶向抑制CASP3减轻肾小管细胞损伤。

本研究纳入95例脓毒症诱导急性肾损伤(SAKI)患者和70例单纯脓毒症患者,检测血清miR-126-5p与CASP3水平。SAKI患者血清miR-126-5p表达下调,且与血清肌酐、胱抑素C、NGAL、KIM-1等肾损伤标志物呈显著负相关。体外实验显示,过表达miR-126-5p可促进LPS刺激的HK-2细胞增殖、抑制凋亡、降低IL-1β、IL-6、TNF-α及氧化应激标志物,并增强SOD活性;CASP3被鉴定为miR-126-5p的直接下游靶点,过表达CASP3可逆转其保护作用。提示miR-126-5p对SAKI具有诊断价值,并可能通过靶向CASP3发挥保护作用。

要点

  • SAKI患者血清miR-126-5p水平较单纯脓毒症患者下调,且与血清肌酐、胱抑素C、NGAL、KIM-1呈显著负相关。
  • 体外LPS刺激HK-2细胞中过表达miR-126-5p可促进增殖、抑制凋亡,并降低IL-1β、IL-6、TNF-α水平。
  • 过表达miR-126-5p可降低ROS和丙二醛、增强超氧化物歧化酶活性,提示减轻氧化应激。
  • 双荧光素酶报告实验证实CASP3为miR-126-5p直接下游靶点,其表达受miR-126-5p负调控。
  • 过表达CASP3可显著逆转miR-126-5p对HK-2细胞的保护效应。

适用人群与场景

  • 脓毒症患者,用于鉴别是否合并急性肾损伤(SAKI);研究纳入95例SAKI和70例单纯脓毒症患者。
  • 原文未提及具体的纳入/排除标准、急诊/ICU/院前场景及病情阶段。

诊断标准与关键阈值

  • 原文未提及SAKI的具体诊断标准(如KDIGO分期、肌酐或尿量阈值)及miR-126-5p的诊断界值。
  • 原文仅报告SAKI患者血清miR-126-5p下调,并与血清肌酐、胱抑素C、NGAL、KIM-1呈显著负相关,未给出诊断阈值或评分。

处置流程与药物剂量

  • 原文未提及针对miR-126-5p的临床治疗剂量、给药途径、频次或目标值。
  • 体外实验采用在LPS刺激的HK-2细胞中过表达miR-126-5p,并非临床给药方案。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的红旗征及相应处理。

研究设计与关键结果

  • 研究类型为临床病例对照研究联合体外细胞实验,纳入95例SAKI患者和70例单纯脓毒症患者,检测血清miR-126-5p和CASP3水平。
  • SAKI患者血清miR-126-5p水平下调,与血清肌酐、胱抑素C、NGAL、KIM-1呈显著负相关(原文未报告具体相关系数及P值)。
  • 体外LPS刺激HK-2细胞中过表达miR-126-5p可促进增殖、抑制凋亡,降低IL-1β、IL-6、TNF-α,降低ROS和丙二醛,增强SOD活性。
  • 双荧光素酶报告实验证实CASP3为miR-126-5p直接靶点,过表达CASP3可显著逆转miR-126-5p的保护作用。
  • 原文未报告miR-126-5p诊断SAKI的ROC曲线、灵敏度、特异度或AUC等诊断效能指标。

证据类型、等级与局限

  • 证据类型:临床病例对照研究联合体外细胞实验(非RCT)。
  • 局限:单中心(原文未明确中心数)、样本量有限(95例SAKI和70例单纯脓毒症)、机制结论主要来自体外HK-2细胞实验,需进一步临床验证。

对床旁实践的改变

  • 原文提示miR-126-5p可能作为SAKI的诊断生物标志物,但未提供诊断阈值或临床验证的效能数据,尚不能直接用于床旁诊断决策。
  • 体外机制提示miR-126-5p通过靶向CASP3减轻肾小管细胞损伤,但尚无临床干预方案,不改变当前SAKI的临床处置。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: As a common and devastating complication of sepsis, sepsis-induced acute kidney injury (SAKI) confers a significant risk of mortality.

PURPOSE: This work focused on the utility of miR-126-5p as a biomarker for SAKI.

METHODS: A total of 95 patients with SAKI and 70 patients with sepsis alone were enrolled. Serum levels of miR-126-5p and Caspase-3 (CASP3) were measured using reverse transcription quantitative polymerase chain reaction. The regulatory interaction between miR-126-5p and CASP3 was validated using a dual-luciferase reporter assay. Cell proliferation, apoptosis, inflammatory cytokine levels, and oxidative stress markers were evaluated using the cell counting kit-8 assay, flow cytometry, enzyme-linked immunosorbent assay, and corresponding commercial kits, respectively.

RESULTS: Serum miR-126-5p levels were downregulated in SAKI patients and showed significant negative correlations with kidney injury markers, including serum creatinine, cystatin C, neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1. Overexpression of miR-126-5p in lipopolysaccharide-stimulated HK-2 cells was shown in vitro to facilitate cell proliferation, restrain apoptosis, and suppress the production of interleukin-1β, interleukin-6, and tumor necrosis factor-α. Concurrently, it reduced oxidative stress markers, reactive oxygen species, and malondialdehyde, and enhanced superoxide dismutase activity. Mechanistically, CASP3 was identified as a direct downstream target of miR-126-5p, and its expression was negatively regulated by miR-126-5p. Furthermore, overexpression of CASP3 significantly reversed the protective effects of miR-126-5p in vitro .

CONCLUSIONS: miR-126-5p showed diagnostic value for SAKI and exerted a protective effect in vitro through targeted regulation of CASP3 expression.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Yuan X, Tan W, Zhang Y, et al. Diagnostic Value of miR-126-5p in Sepsis-Induced Acute Kidney Injury and its Molecular Mechanism via CASP3. Shock. 2026. PMID: 42401483. doi:10.1097/SHK.0000000000002905

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。